Business
Atossa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary (Z)-endoxifenStrengthened
About this update from Atossa Therapeutics, Inc.
[{"type":"text","content":"Achieved significant enrollment milestones in three ongoing Phase 2 clinical trialsBroadened patent protection for proprietary (Z)-endoxifenStrengthened management team with appointment of Greg Weaver as Chief Financial OfficerEnded second quarter 2023 with $99.4 million of cash and cash equivalents SEATTLE, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces financial results for the quarter ended June 30, 2023, and provides an update on recent company developments. Key developments from Q2 2023 and year to date include: Clinical Highlights Full Enrollment and Completion of 40 mg/day Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial – the PK run-in cohort is designed to identify the appropriate dose of (Z)-endoxifen to deliver the steady state plasma concentrations required to effectively target PKC beta 1 inhibition and further enhance (Z)-endoxifen’s antitumor mechanism of action.70% Enrollment in Ongoing Phase 2 Karisma-Endoxifen Clinical Trial – the study is investigating (Z)-endoxifen in premenopausal women with measurable breast density. Participants receive daily doses of (Z)-endoxifen for six months, over the course of which mammograms are conducted to measure reduction in breast density. Full enrollment is expected by year-end 2023 with data expected in 2024.30% Enrollment in Phase 2 I-SPY 2 Clinical Trial – (Z)-endoxifen is being evaluated as a neoadjuvant treatment in a study arm of the ongoing I-SPY 2 clinical trial. The study arm targets patients with newly diagnosed estrogen receptor-positive invasive breast cancer whose tumors are predicted to be sensitive to endocrine therapy but for whom chemotherapy is expected to provide little or no benefit. Approximately 20 patients will be treated with (Z)-endoxifen for up to 24 weeks prior to surgery.Approval from Health Canada to Conduct Phase 2 EVANGELINE Clinical Trial in Canada – Atossa was authorized to open sites and enroll patients in the Phase 2 EVANGELINE study throughout Canada. Corporate Highlights Appointment of Greg Weaver as Chief Financial Officer – Mr. Weaver has over 30 years of life sciences, financial and operations executive experienc...